secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001140361-24-035951
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres sells VOWST business to Nestlé for up to $100M cash plus milestones; issues $15M stock
--------------------------------------------------------------------------------

- Cash payment of $100M at closing (net of ~$17.9M owed to Nestlé affiliate and ~CHF2M to Bacthera); $50M due Jan 2025, $25M July 2025.
- Prepaid $60M milestone for $150M annual net sales; future milestones of $125M at $400M and $150M at $750M in sales.
- Seres and Nestlé share 50/50 net profit/loss on VOWST in 2025 profit-sharing period.
- Nestlé to purchase 14,285,715 shares at $1.05/share ($15M); Seres to register resale within 90 days.
- Post-closing Seres to focus on SER-155 and other biotherapeutic candidates; stockholder vote required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000114036124035951/0001140361-24-035951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000114036124035951/ny20030749x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-035951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer